

www.elsevier.nl/locate/carres

CARBOHYDRATE RESEARCH

Carbohydrate Research 329 (2000) 745-754

Synthesis of (25R)-ruscogenin-1-yl β -D-xylopyranosyl- $(1 \rightarrow 3)$ - $[\beta$ -D-glucopyranosyl- $(1 \rightarrow 2)$]- β -D-fucopyranoside

Meizheng Liu^a, Biao Yu^{a,*1}, Xiangyang Wu^a, Yongzheng Hui^{a,*2}, Kwok-Pui Fung^b

^aState Key Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China ^bDepartment of Biochemistry, The Chinese University of Hong Kong, Hong Kong

Received 15 June 2000; accepted 8 August 2000

Abstract

The synthesis of (25R)-ruscogenin-1-yl β -D-xylopyranosyl- $(1 \rightarrow 3)$ -[β -D-glucopyranosyl- $(1 \rightarrow 2)$]- β -D-fucopyranoside, a saponin from the tuber of *Liriope muscari* (Decne.) Bailey, is described. © 2000 Elsevier Science Ltd. All rights reserved.

Keywords: (25R)-Ruscogenin-1-yl β -D-xylopyranosyl- $(1 \rightarrow 3)$ -[β -D-glucopyranosyl- $(1 \rightarrow 2)$]- β -D-fucopyranoside; Saponin; Synthesis

1. Introduction

Various *Ophiopogon* and *Liriope* species have been commonly used as a traditional Chinese herbal medicine under the name of Maidong, which possesses tonic effects [1]. Saponins are believed to be the active principles in Maidong plants. Thus far, more than 60 steroidal saponins have been isolated from these species, and most of these saponins are (25R or 25S)-ruscogenin-1-yl saponins [1]. Saponin 1, namely (25R)-ruscogenin-1-yl β -Dxylopyranosyl- $(1 \rightarrow 3)$ - $[\beta$ -D-glucopyranosyl- $(1 \rightarrow 2)]$ - β -D-fucopyranoside, with the typical structure, has been isolated from *Liriope mus*- *cari* (Decne.) Bailey [2]. This saponin was reported to have strong in vivo anti-inflammatory and immunopharmacological activities [3]. Herein, we report a total synthesis of this saponin [4].

2. Results and discussion

Saponin 1 was retrosynthetically disconnected into trisaccharide donor 2 and steroid acceptor 3 (Scheme 1). Trichloroacetimidate donor 2, which lacks a functional group for neighboring-group participation, was envisioned to achieve the formation of the desired β D-glycosidic linkage via an SN2 reaction [5]. Steroid 3 would conceivably be derived from diosgenin by introduction of a 1 β -OH. The 3-OH of 3 was believed to be more active than the 1 β -OH and would, therefore, be protected as a TBS ether.

E-mail address: byu@pub.sioc.ac.cn (B. Yu).

¹ *Corresponding author. Tel.: + 86-21-64163300; fax: + 86-21-64166128.

² *Corresponding author.



Scheme 1. Retrosynthesis of saponin 1.

As shown in Scheme 2, the β -OH was readily introduced onto C-1 of the commercially available diosgenin using a similar strategy to that employed in the conversion of cholestanetype steroids into vitamin D and its analogues

[6]. Oxidation of diosgenin with DDQ gave the trienone 4, which was further oxidized with H₂O₂ in the presence of NaOMe to provide the epoxide 5. The transformation of epoxide 5 into diol under Li/NH₃ reduction conditions was found to be capricious. Both Δ^5 -1 α ,3 β -diol 6, Δ^6 -1 α ,3 β -diol 7 and several other unidentified products were produced in varying amounts. Under carefully controlled anhydrous conditions, 6 was obtained in $\sim 50\%$ yield, without any isomer 7 being detected. If a proton source was provided during the reduction by repeatedly charging with solid NH₄Cl [7], 7 turned out to be the major product (42%). The ¹H NMR spectrum of 6showed one broad doublet at 5.50 ppm (J 5.2 Hz) for H-6, while that of 7 showed two doublets at 5.39 ppm (J 10.0 Hz) and 5.28 ppm (J 10.0 Hz), respectively, for H-6 and H-7. was Diol 6 treated with tertbutylchlorodimethylsilane and imidazole in DMF to give 8. Subsequently, attempts to invert the 1α -OH of **8** into the β configuration



Scheme 2. Reagents and conditions: (a) DDQ, dioxane, reflux, 8 h, 69%; (b) H_2O_2 , NaOMe, MeOH, rt, overnight, 68%; (c) Li/NH₃, THF, then NH₄Cl, ~ 50% (for 6); (d) TBSCl, imidazole, DMF, rt, overnight, 100%; (e) PDC, CH₂Cl₂, rt, 92%; (f) NaBH₄, THF, 70% (for 3); (g) Ac₂O, DMAP, pyridine, 94%; (h) 5 N HCl, acetone, rt, 1 h, 96%.



Scheme 3. Reagents and conditions: (a) 3% HCl, AllOH, 80 °C, 93%; (b) $(CH_3)_2(OCH_3)_2$, TsOH (0.1 equiv), rt, 83%; (c) 14, BF₃·Et₂O (0.7 equiv), CH₂Cl₂, 4 Å molecular sieves, -20 °C, 73%; (d) 50% HOAc, 60 °C, 93%; (e) CH₃C(OCH₃)₃, TsOH (0.1 equiv), rt, 20 min, then 20% HOAc, rt, overnight, 87%; (f) 18, BF₃·Et₂O (0.7 equiv), CH₂Cl₂, 4 Å molecular sieves, -20 °C, 90%; (g) $ICF_2(CF_2)_4CF_2Cl$, Na₂S₂O₄, NaHCO₃, CH₃CN-H₂O, rt; (h) Zn, NH₄Cl, EtOH, reflux, 76% (2 steps); (i) Cl₃CCN, DBU, CH₂Cl₂, 81%.

by the Mitsunobu reaction [8] were unsuccessful. It could be explained that the reaction center at C-1 of 8 was seriously hindered by the methyl group at C-19 and the TBSO group at C-3. Therefore, an oxidation-reduction sequence was utilized to effectively epimerize the 1α -OH of 8. Thus, 8 was oxidized by PDC to give ketone 9 (92%). Reduction of 9 with NaBH₄ mainly provided the expected 1 β -OH product 3 (70%), with 8 being obtained in 25% yield. This stereoselectivity can be attributed to the bulkiness of TBS substitution on 3β-OH. Because in similar cases without 3-substitution, the 1α -epimer was the predominant product [9]. In order to confirm its structure, $\mathbf{3}$ was acetylated to give ester 10. The ¹H NMR signal for H-1 was moved downfield from 3.50 ppm (in 3) to 4.58 ppm (dd, J 11.9, 4.4 Hz), and an obvious NOE signal showed up between H-1 and H-3 of 10. Furthermore, desilylation of 3 with 5 N HCl afforded (25R)-ruscogenin, whose physical data was identical to that of an authentic sample.

Trisaccharide trichloroacetimidate 2 was synthesized as shown in Scheme 3. 1,2:3,4-Di-O-isopropylidene- α -D-fucopyranoside (11). readily prepared from galactose in three steps [10], was treated with 3% HCl in allyl alcohol to give ally α -D-fucopyranoside 12 in high yield (93%). Treatment of 12 with 2,2dimethoxypropane and a catalytic amount of TsOH provided 13 with the 2-OH free. Glycosylation of 13 with 2,3,4,6-tetra-O-acetyl-Dglucopyranosyl trichloroacetimidate (14) with promotion of $BF_3 \cdot OEt_2$ led to the disaccharide 15 in good yield (73%). Removal of the O-isopropylidene group with 50% HOAc readily afforded diol 16. Since it has been commonly found that the equatorial 3-OH is more active than the axial 4-OH for galactopyranose, arabinopyranose and fucopyranose derivatives [11], a regioselective glycosylation of 16, giving a $1 \rightarrow 3$ linked product, was expected. However, glycosylation of 16 with 2,3,4-tri-Oacetyl-D-xylopyranosyl trichloroacetimidate (18) with promotion by BF_3 ·OEt₂ gave a mixture of the 3-O-, 4-O-, and 3,4-di-O-xylosy-



Scheme 4. Reagents and conditions: (a) TMSOTf (0.2 equiv), $-5 \sim 0$ °C, CH₂Cl₂, 4 Å molecular sieves, 2 h, 69% (for 22); (b) TMSOTf (2.0 equiv), -78 °C, CH₂Cl₂, 5 min; (c) MeONa–MeOH, rt, 3 h, 85%.

lated products in comparable amounts. Therefore, diol 16 was acetylated in a regioselective manner at 4-OH by treatment with triethylorthoacetate and a catalytic amount of TsOH, followed with 20% HOAc, providing 17 in 87% yield [12]. 2D ¹H NMR analysis of 17 showed that the signal at 5.25 ppm (t, J 3.4 Fuc-H-4 Hz) corresponding to moved downfield from 4.00 ppm in 16 to 5.25 ppm, demonstrating that only the 4-OH of 17 was masked with an acetyl group. Subsequently, 17 was easily xylosylated with 18 to give the desired trisaccharide 19 in high yield (90%). ¹H NMR analysis of **19** showed that the signals for the anomeric protons were at 4.98 ppm (d, $J_{1,2}$ 3.2 Hz), 4.59 ppm (d, $J_{1',2'}$ 7.8 Hz), and 4.64 ppm (d, $J_{1'',2''}$ 6.3 Hz), respectively, indicating that the desired glycosidic linkages of 1α , $1'\beta$, and $1''\beta$ were obtained.

Deallylation of trisaccharide **19** using PdCl₂ in HOAc [13], followed by treatment with CCl₃CN and DBU, afforded the trisaccharide trichloroacetimidate **2** in 43% yield. The relatively low yield of the above transformation resulted from side reactions during deallylation under PdCl₂. For example, Wacker oxidation products were produced in considerable amounts, which were inseparable from the deallylation product **20** [14,15]. Therefore, we applied our recently developed method for deallylation [15]. Treatment of **19** with C₆ClF₁₂I and Na₂S₂O₄-NaHCO₃ in CH₃CN-H₂O provided the corresponding β-iodido-γperfluoroalkane derivative, which was then eliminated under Zn and NH₄Cl in EtOH to afford **20** in 76% yield. Addition of **20** with CCl₃CN afforded **2** in 81% yield. Trichloroacetimidate **2** was confirmed to be in the α configuration by ¹H NMR analysis: δ 6.40 (d, 1 H, J 3.5 Hz, H-1).

With donor 2 and acceptor 3 at hand, we sought to effect the final glycosylation to assemble the target saponin 1 (Scheme 4). However, coupling of 3 with trichloroacetimidate donors (either trisaccharide donor 2 or simple monosaccharide donor 21 [16]) under normal conditions for Schmidt's glycosylation [5] was found to be difficult, conceivably due to the steric hindrance of the 1β -OH of **3**. Finally, employing Schmidt's 'inverse procedure' [17] in which the acceptor 3 was first activated by a catalytic amount of TMSOTf before addition of the glycosyl donors (21 or 2), we obtained the desired glycosylation products 22 (69%) and 23 (46%, together with 10% of its α anomer), respectively. ¹H NMR analysis of 23 showed the signals for three anomeric protons at 4.89 ppm (d, J 7.8 Hz), 4.84 ppm (d, J 7.7 Hz), and 4.31 ppm (d, J 7.3 Hz), respectively, representing that the expected glycosidic $1'\beta$, $1''\beta$, $1'''\beta$ linkages were obtained. Desilylation of 23 with 2.0 equivalents of TMSOTf under low temperature (-78 °C) cleanly afforded the desired desilvlated product (on TLC),[18] which was directly subjected to NaOMe-MeOH to furnish saponin 1 in 85% yield. The physical data for the synthetic sample was in good agreement with those reported [2].

3. Experimental

General methods.—See Ref. [19].

(25R)-Spirostan-1,4,6-triene-3-one (4).—A solution of diosgenin (4.49 g, 10.8 mmol) and dichlorodicyanobenzoquinone (DDO) (7.38 g. 30.5 mmol) in dioxane (200 mL) was heated under reflux for 8 h, and then cooled, filtered and applied to a short column of silica gel (CH_2Cl_2) to gave a crude product, which was further purified by a silica gel column chromatography (3:1 petroleum ether-EtOAc) to afford **4** (3.04 g, 69%) as a white solid: mp 194–195 °C; $[\alpha]_{D}^{20} - 109.5^{\circ}$ (*c* 0.1, CHCl₃); IR (KBr); v 2972 (s), 1668 (s), 1049 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₂): δ 7.04 (d, 1 H, J 10.0 Hz), 6.23 (d, 2 H, J 9.8 Hz), 6.02 (d, 1 H, J 13.3 Hz), 6.00 (s, 1 H), 4.42 (dd, 1 H, J 14.2, 7.5 Hz), 3.47 (m, 1 H), 3.35 (t, 1 H, J 10.9 Hz), 1.21 (s, 3 H), 0.97 (d, 3 H, J 6.9 Hz), 0.90 (s, 3 H), 0.80 (d, 3 H, J 6.2 Hz); EIMS (m/z): 409 $[M^+ + 1]$, 408 $[M^+]$; HREIMS (m/z): for $C_{27}H_{36}O_3$: 408.2664. Calcd Found: 408.2637.

 $1\alpha, 2\alpha$ - Epoxy - (25R) - spirostan - 4,6 - dien - 3one (5).— H_2O_2 (30%, 1 mL) was added to a solution of trienone 4 (30 mg, 0.073 mmol) in MeOH (20 mL) containing 0.2% NaOMe. The mixture was stirred at 15 °C overnight and then diluted with ether (20 mL). The organic layer was dried and concentrated. The residue was purified by a silica gel column chromatography (3:1 petroleum ether-EtOAc) to give 5 (21.2 mg, 68%) as a white solid: mp 167– 168 °C; $[\alpha]_{D}^{20} - 17.1^{\circ}$ (c 0.23, CHCl₃); IR (KBr): v 2981 (s), 1730 (s), 1670 (s), 1620, 1460, 1080 (m) cm^{-1} ; ¹H NMR (300 MHz, CDCl₂): δ 6. 08 (m, 2 H), 5.66 (d, 1 H, J 0.9 Hz), 4.44 (q, 1 H, J 10.0 Hz), 3.59 (d, 1 H, J 4.1 Hz), 3.48–3.45 (m, 2 H), 3.40 (t, 1 H, J 10.8 Hz), 1.20 (s, 3 H), 0.98 (d, 3 H, J 6.9 Hz), 0.90 (s, 3 H), 0.80 (d, 3 H, J 6.3 Hz); EIMS (m/z): 425 [M⁺ + 1], 424 [M⁺]; HREIMS (m/z)z): Calcd for $C_{27}H_{36}O_4$ 424.2614. Found: 424.2649.

(25R)-Spirostan-5-en-1 α , 3β -diol (6).—A three-necked flask was fitted with a dropping funnel, a cold-finger condenser filled with solid CO₂, and an inlet tube connected to an ammonia source, with gas drying by KOH. Argon was swept through the system for 10

min, and then ammonia (100 mL) was trapped in the flask. Lithium wire was cut into short pieces and added. After being stirred for 1 h, epoxide 5 (100 mg, 0.23 mmol) in THF (10 mL) was added dropwise during 30 min. The cooling bath was removed, and the mixture was allowed to warm to -40 °C for 20 min. The flask was dipped in a cooling bath and anhvdrous NH₄Cl was added during 2 h (note: take care! vigorous reaction). The mixture turned white and pasty. Most of the ammonia was removed in a stream of argon. The residue was diluted with ether, washed with brine and dried. Evaporation left a white solid that was applied to a silica gel column (1:1 petroleum ether-EtOAc) to afford 6 (54 mg, 53%) as a white solid: mp > 230 °C; $[\alpha]_{\rm D}^{20} - 160.7^{\circ}$ (c 0.54, CHCl₃); IR (KBr); v 3441, 2954, 920, 900 cm⁻¹ (intensity 900 > 920). ¹H NMR (300 MHz, CDCl₃): δ 5.50 (brd, 1 H, J 5.7 Hz), 4.40 (q, 1 H, J 7.1 Hz), 3.51–3.31 (m, 4 H), 1.00 (s, 3 H), 0.92 (d, 3 H, J 6.8 Hz), 0.78 (m, 6 H); ¹³C NMR (75 MHz. $CDCl_3$): δ 137.30, 125.39, 109.27, 80.73, 72.85, 66.83, 66.36, 62.05, 56.34, 41.83, 41.67, 41.36, 40.22, 39.48, 38.22, 31.86, 31.36, 30.27, 29.66, 28.78, 20.07, 19.46, 17.10, 16.23, 14.47; EIMS (m/z): 431 [M⁺ + 1], 430 [M⁺], 412 (M⁺ -H₂O).

(25R)-Spirostan-6-en- 1α , 3β -diol (7).-Asolution of epoxide 5 (100 mg, 0.23 mmol) in dry liquid NH₃ (10 mL) and THF (10 mL) at -78 °C under argon was stirred for 1 h and warmed up to -30 °C. To the above solution, NH₄Cl (110 mg) was added, followed by lithium pieces (12 mg). After the blue color faded, the addition of NH₄Cl (80 mg) and lithium pieces (12 mg) was repeated six times. After the mixture was kept blue for 2 h, the reaction was charged with NH₄Cl at -78 °C, then diluted with EtOAc (20 mL). The organic layer was washed with brine, dried over Na₂SO₄ and then concentrated. The residue was purified by a silica gel column chromatography (1:1 petroleum ether-EtOAc) to give 7 (42 mg, 42%) as a white solid: mp > 230 °C; $[\alpha]_{D}^{20} - 167.8^{\circ}$ (c 0.33, CHCl₃); IR (KBr): v 3441, 2954, 920, 900 cm⁻¹ (intensity 900 >920). ¹H NMR (300 MHz, CDCl₃): δ 5.40 (brd, 1 H, J 12.0 Hz), 5.28 (brd, 1 H, J 12.0

Hz), 4.35 (m, 1 H), 3.98 (m, 1 H), 3.79 (t, 1 H), 3.41 (m, 1 H), 3.31 (t, 1 H, *J* 10.8 Hz), 0.90 (d, 3 H, *J* 6.8 Hz), 0.75 (s, 3 H), 0.74 (s, 3 H), 0.72 (d, 3 H, *J* 6.3 Hz); ¹³C NMR (75 MHz, CDCl₃): δ 130.72, 128.03, 109.25, 80.81, 72.02, 67.21, 66.83, 62.07, 54.14, 46.60, 41.52, 39.80, 38.65, 38.42, 37.77, 36.96, 35.95, 31.58, 31.35, 30.24, 28.75, 20.45, 17.10, 16.48, 14.46, 12.47; EIMS (*m*/*z*): 431 [M⁺ + 1], 430 [M⁺], 412 [M⁺ – H₂O]; HREIMS (*m*/*z*): Calcd for C₂₇H₄₂O₄: 430.3083. Found: 430.3095.

 3β - O - tert - Butyldimethylsilyl - (25R) - spiro stan-5-en- 1α -ol (8).—A solution of 6 (342 mg, 0.80 mmol), *tert*-butylchlorodimethylsilane (145 mg, 0.96 mmol), and a catalytic amount of imidazole in DMF (8 mL) was stirred overnight. The mixture was poured into water and extracted with EtOAc. The combined extracts were washed with aq NaHCO₃, brine and water, respectively, and then dried over Na_2SO_4 and concentrated to dryness. The residue was purified by a silica gel column (6:1 petroleum ether-EtOAc) to afford 8 (218 mg, 100%) as a white solid: mp > 230 °C; $[\alpha]_D^{20}$ $+338.7^{\circ}$ (c 0.11, CHCl₃); ¹H NMR (CDCl₃): δ 5.50 (brd, 1 H, J 5.2 Hz), 4.35 (q, 1 H, J 7.1 Hz), 3.87 (m, 1 H), 3.75 (brs, 1 H), 3.41 (m, 1 H), 3.31 (t, 1 H, J 10.8 Hz), 0.98 (s, 3 H), 0.91 (d, 3 H, J 6.7 Hz), 0.82 (s, 9 H), 0.74 (d, 3 H), 0.70 (d, 3 H), 0.01(s, 6 H); EIMS (m/z): 526 $[M^+ - H_2O]$, 487 (M⁺ - 'Bu). Anal. Calcd for C₃₃H₅₆O₄Si: C 72.74; H 10.37. Found: C 72.62; H 10.67.

 3β - O - tert - Butyldimethylsilyl - (25R) - spiro stan-5-en-1-one (9).—To a solution of 8 (79 mg, 0.15 mmol) in CH₂Cl₂ (5 mL) was added pyridinium dichromate (PDC, 100 mg). The mixture was stirred at rt for 1 h and then filtered through a pad of Celite. The filtrates were concentrated. The residue was purified by silica gel column chromatography (20:1 petroleum ether-EtOAc) to give 9 (72 mg, 92%) as a white solid: mp 215–216 °C; $[\alpha]_{D}^{20}$ -25.8° (c 0.06, CHCl₃); IR (KBr); v 2955, 2859, 1708 (s), 921, 901 cm⁻¹ (intensity 901 > 921). ¹H NMR (300 MHz, CDCl₃): δ 5.59 (brd, 1 H, J 5.3 Hz), 4.41 (m, 1 H), 3.74 (m, 1 H), 3.47 (m, 1 H), 3.37 (t, 1 H, J 10.6 Hz), 0.97 (d, 3 H, J 6.7 Hz), 0.94 (s, 12 H), 0.79 (d, 3 H), 0.78 (s, 3 H), 0.06 (s, 3 H), 0.05 (s, 3 H); EIMS (m/z): 543 $[M^+ + 1]$, 542 $[M^+]$, 527

 $(M^+ - Me)$, 485 $[M^+ - {}^{\prime}Bu$, 100%]. Anal. Calcd for $C_{33}H_{54}O_4Si$: C, 73.01; H, 10.03. Found: C, 73.02; H 10.50.

 3β - O - tert - Butyldimethylsilyl - (25R) - ruscogenin (3).—To a solution of 9 (110 mg, 0.20 mmol) in dry THF (20 mL) was added NaBH₄ (67 mg, 0.20 mmol). After being stirred at rt for 2 h, the reaction was quenched by addition of water (0.1 mL). The mixture was then concentrated in vacuo. The residue was purified by silica gel column chromatography (6:1 petroleum ether-EtOAc) to give 8 (27 mg, 25%) and 3 (77 mg, 70%) as white solids. 3: mp > 230 °C; $[\alpha]_{D}^{20} - 76.3^{\circ}$ (c 0.11, CHCl₃); IR (KBr); v 3481, 2953, 2860, 1045, 921, 900 cm^{-1} (intensity 900 > 921); ¹H NMR (300 MHz, CDCl₃): δ 5.51 (brd, 1 H, J 5.6 Hz), 4.40 (g, 1 H, J 6.7 Hz), 3.55–3.39 (m, 4 H), 1.03 (s, 3 H), 0.91 (d, 3 H, J 6.7 Hz), 0.88 (s, 9 H), 0.79 (d, 3 H, J 6.0 Hz), 0.78 (s, 3 H), 0.09 (s, 6 H); EIMS (m/z): 544 [M⁺], 543 $[M^+ - 1]$, 526 $[M^+ - H_2O]$, 487 $[M^+ - {}^tBu]$. Anal. Calcd for $C_{33}H_{56}O_4Si$: C, 72.74; H, 10.37. Found: C, 72.34; H, 10.39.

 1β -O-Acetvl- 3β -O-tert-butyldimethylsilyl-(25R)-ruscogenin (10).—A solution of 3 (10 mg, 0.018 mmol) in Ac_2O and pyridine (1:1, 2) mL) was stirred overnight and then concentrated with toluene to dryness. The residue was purified by a silica gel column chromatography (15:1 petroleum ether-EtOAc) to afford 10 (10 mg, 94%) as a white solid: mp. 210–211 °C; $[\alpha]_{\rm D}^{20}$ – 120.7° (c 0.25, CHCl₃); ¹H NMR (300 MHz, CDCl₂): δ 5.54 (brd, 1 H, J 5.2 Hz), 4.58 (dd, 1 H, J 11.9, 4.4 Hz), 4.38 (m, 1 H), 3.56–3.46 (m, 3 H), 3.36 (t, 1 H, J 10.7), 0.95 (d, 3 H, J 6.9 Hz), 0.87 (s, 12 H), 0.79 (d, 3 H, J 5.8 Hz), 0.77 (s, 3 H), 0.05 (s, 3 H), 0.04 (s, 3 H); EIMS (m/z): 587 $[M^+ + 1]$, 586 $[M^+]$, 585 $[M^+ - 1]$, 529 $[M^+$ $-^{t}Bu$].

(25R)-Ruscogenin.—To a solution of **3** (10 mg, 0.018 mmol) in acetone (5 mL) was added 5 N HCl (0.5 mL). After stirring at rt for 1 h, the solution was diluted with EtOAc (20 mL). The organic extract was washed with 5% NaHCO₃, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was purified by silica gel column chromatography (1:1 petroleum ether–EtOAc) to give

(25*R*)-ruscogenin (7.6 mg, 96%) as a white solid: mp > 230 °C; $[\alpha]_D^{20} - 91.4^\circ$ (*c* 0.50, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 5.54 (brd, 1 H, *J* 5.6 Hz), 4.40 (m, 1 H), 3. 56 (m, 1 H), 3.48–3.41 (m, 2 H), 3.37 (t, 1 H, *J* 10.9 Hz), 1.05 (s, 3 H), 0.99 (d, 3 H, *J* 6.1 Hz), 0.97 (d, 3 H, *J* 6.6 Hz), 0.80 (s, 3 H). ¹³C NMR: 138.2, 125.4, 109.3, 80.8, 77.9, 68.1, 66.9, 62.3, 56.5, 50.4, 42.9, 42.4, 42.0, 41.7, 40.1, 39.9, 32.4, 32.04, 32.0, 31.4, 30.3, 28.8, 23.8, 17.1, 16.3, 14.5, 13.0; EIMS (*m*/*z*): 430 [M⁺], 412 [M⁺ - H₂O]; HREIMS (*m*/*z*): Calcd for C₂₇H₄₂O₄: 430.3083. Found: 430.3047.

Allyl α -D-fucopyranoside (12).—1,2;3,4-Di-O-isopropylidene- α -D-fucopyranoside (11)(5.93 g, 24.3 mmol) was suspended and heated in a allyl alcohol solution (100 mL) containing 3% HCl at 80 °C for 2 h until the solution became clear. The resulting solution was then concentrated in vacuo to afford a colorless residue, which was purified by silica gel chromatography (15:1 column CHCl₃-MeOH) to give 12 (4.99 g, 93%) as a white solid: $[\alpha]_{D}^{20} + 42.9^{\circ}$ (*c* 0.8, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 5.93 (m, 1 H), 5.32 (m, 1 H), 4.88 (d, 1 H, J 3.7 Hz), 4.15 (m, 1 H), 4.08–3.98 (m, 2 H), 3.84–3.68 (m, 3 H); EIMS (m/z): 205 [M⁺ + 1], 147 [M⁺ - OAll, 100%]. HREIMS (m/z): Calcd for C₀H₁₆O₅ + 1-H₂O: 187.0892. Found: 187.0945.

Allvl 3,4-O-isopropylidene- α -D-fucopyranoside (13).—To a solution of 12 (3.0 g, 0.015 mol) and 2,2-dimethoxypropane (4.7 mL, 0.036 mol) in CH₂Cl₂ (10 mL) was added a catalytic amount of p-TsOH·H₂O. After stirring overnight, the mixture was neutralized with triethylamine and then concentrated. The residue was purified by silica gel column chromatography (4:1 petroleum-EtOAc) to give 13 (2.98 g, 83%) as a white solid: mp 47– 48 °C; $[\alpha]_{D}^{20}$ + 19.7° (c 0.5, CHCl₃); ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3)$: δ 5.91 (m, 1 H), 5.29–5.20 (m, 2 H), 4.86 (d, 1 H, J 3.9 Hz), 4.24 (dd, 1 H, J 12.4, 4.0 Hz), 4.21 (dd, 1 H, J 6.4, 6.0 Hz), 4.13 (ddd, 1 H, J 12.3, 6.9, 1.3 Hz), 4.05 (m, 1 H), 4.04 (m, 1 H), 3.79 (m, 1 H), 1.51 (s, 3 H), 1.34 (s, 3 H), 1.31 (d, 3 H); EIMS (m/z): 245 $[M^+ + 1]$, 229 $[M^+ - CH_3]$, 187 $[M^+ -$ OAll, 100%]; HREIMS (m/z): Calcd for C₁₂H₂₀O₅: 244.1311. Found: 244.1296.

Allyl(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- $(1 \rightarrow 2)$ -3,4-O-isopropylidene- α -D-fucopyranoside (15).—To a suspension of 13 (0.96 g, 3.94 mmol), trichloroacetimidate 14 (2.13 g, 4.33 mmol), and 4 Å molecular sieves (1.0 g)in dry CH₂Cl₂ (10 mL) under argon at -40 °C, was added BF₃·Et₂O (0.25 mL, 1.87 mmol) dropwise. After stirring for 3 h, the mixture was treated with satd aq $NaHCO_3$ (1) mL) and then diluted with CH_2Cl_2 (100 mL). The organic layer was separated, dried with sodium sulfate and then concentrated in vacuo. The residue was purified by silica gel column chromatography (3:1 petroleum-EtOAc) to give 15 (1.65 g, 73%) as a white solid: mp 81–82 °C; $[\alpha]_{D}^{20}$ + 47.0° (c 0.36, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 5.87 (m, 1 H), 5.29–5.02 (m, 5 H), 4.88 (d, 1 H, J 3.5 Hz), 4.86 (d, 1 H, J 7.9 Hz), 4.26–4.10 (m, 5 H), 4.02–3.98 (m, 2 H), 3.78 (m, 1 H), 3.67 (m, 1 H) 2.07, 2.03, 2.00, 1.95 (s each, 3 H each), 1.50, 1.33 (s each, 3 H each), 1.32 (d, 3 H, J 6.5 Hz); EIMS (m/z): 559 $[M^+ - CH_3]$. Anal. Calcd for C₂₆H₃₈O₁₄: C, 54.35; H, 6.62. Found: C, 53.97; H, 6.84.

Allyl(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosvl)- $(1 \rightarrow 2)$ - α -D-fucopyranoside (16).—A solution of 15 (1.58 g, 0.75 mmol) in 50% AcOH (26 mL) was heated at 60 °C for 1.5 h and then concentrated in vacuo. The residue was purified by silica gel column chromatography (1:1 petroleum-EtOAc) to afford 16 (1.36 g, 93%) as a white solid: mp 131–132 °C; $[\alpha]_{D}^{20}$ $+89.4^{\circ}$ (c 0.1, CHCl₃); ¹H NMR (300 MHz, $CDCl_3$): δ 5.92 (m, 1 H), 5.30 (dd, 1 H, J 17.3, 1.5 Hz), 5.21 (t, 1 H, J 9.4 Hz), 5.17 (t, 1 H, J 10.3 Hz), 5.06 (t, 1 H, J 9.7 Hz), 5.04 (dd, 1 H, J 9.4, 8.0 Hz), 4.98 (d, 1 H, J 3.1 Hz), 4.78 (m, 1 H), 4.20–3.97 (m, 6 H), 3.87 (t, 1 H, J 9.7 Hz), 3.84 (m, 1 H), 3.70 (m, 1 H), 2.08, 2.05, 2.03, 2.00 (s each, 3 H each), 1.28 (d, 3 H, J 6.5 Hz); ESIMS (m/z): 573 [M + K⁺], 557 $[M + Na^+]$, 553 $[M^+ + 1 + H_2O]$. Anal. Calcd for $C_{23}H_{34}O_{14}$: C, 51.66; H, 6.41. Found: C, 51.38; H 6.24.

Allyl(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)- $(1 \rightarrow 2)$ -4-O-acetyl- α -D-fucopyranoside (17).—To a solution of 16 (1.40 g, 2.62 mmol) in CH₂Cl₂ (20 mL) was added triethyl orthoacetate (2.2 mL) and *p*-TsOH·H₂O (10 mg). After stirring at rt for 20 min, 20% HOAc (15 mL) was added, and the mixture was vigorously stirred overnight. CH₂Cl₂ (40 mL) was added to the mixture, and the solution was sequentially washed with water, aq NaHCO₃ and water. It was then dried and concentrated to a residue. The residue was purified by silica gel column chromatography (1:1 petroleum–EtOAc) to give (17) (1.32 g, 87%) as a white solid: mp 109–110 °C; $[\alpha]_{D}^{20}$ $+63.3^{\circ}$ (c 0.39, CHCl₃); ¹H NMR (600 MHz, $CDCl_3$): δ 5.92 (m, 1 H), 5.30–5.25 (m, 2 H), 5.21 (t, 1 H, J 9.5 Hz), 5.18 (t, 1 H, J 10.3 Hz), 5.07 (t, 1 H, J 9.7 Hz), 5.04 (dd, 1 H, J 9.6, 9.2 Hz), 5.01 (d, 1 H, J 3.4 Hz), 4.78 (d, 1 H, J 7.9 Hz), 4.20–4.15 (m, 4 H), 4.10 (m, 1 H), 4.05 (t, 1 H, J 12.8 Hz), 3.80 (m, 1 H, J 9.9 Hz), 3.72 (m, 1 H), 2.18, 2.08, 2.04, 2.03, 2.00 (s each, 3 H each), 1.13 (d, 3 H, J 6.7 Hz); ESIMS (m/z): 615 [M + K⁺], 599 [M + Na⁺], 594 (M⁺ + H₂O). Anal. Calcd for C₂₅H₃₆O₁₅: C, 52.06; H, 6.30. Found: C, 52.08; H. 6.37.

Allyl(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- $(1 \rightarrow 2)$ - $[(2,3,4-tri-O-acetyl-\beta-D-xylo$ pyranosyl)- $(1 \rightarrow 3)$]-4-O-acetyl- α -D-fucopyranoside (19).—To a suspension of 17 (820 mg, 1.42 mmol), trichloroacetimidate 18 (659 mg, 1.56 mmol), and 4 Å molecular sieves (1.0 g)in dry CH₂Cl₂ (6 mL) under argon at -40 °C, was added BF₃·Et₂O (0.12 mL, 0.11 mmol) dropwise. After stirring for 3 h, the reaction mixture was treated with satd aq NaHCO₃ (4 mL) and then diluted with CH_2Cl_2 (20 mL). The organic layer was separated, dried over sodium sulfate and concentrated in vacuo. The residue was purified by column silica gel chromatography (1:1)petroleum-EtOAc) to give 19 (0.74 g, 90%)and recovered 18 (250 mg) as white solids. 19: mp 85–86 °C; $[\alpha]_{D}^{20}$ + 130.6° (c 0.13, CHCl₃); ¹H NMR (600 Hz, CDCl₃): δ 5.91 (m, 1 H), 5.32-5.23 (m, 2 H), 5.19 (d, 1 H, J 10.4 Hz), 5.13 (t, 1 H, J 9.3 Hz), 5.06 (t, 1 H, J 10.0 Hz), 5.07 (t, 1 H, J 9.1 Hz), 5.02 (dd, 1 H, J 8.8, 8.5 Hz), 4.98 (d, 1 H, J 3.2 Hz), 4.94 (m, 1 H), 4.87 (dd, 1 H, J 8.7, 6.5 Hz), 4.64 (d, 1 H, J 6.3 Hz), 4.59 (d, 1 H, J 7.8 Hz), 4.22 (dd, 1 H, J 12.0 Hz), 4.15 (m, 2 H), 4.11 (m, 1 H), 4.10-4.04 (m, 2 H), 3.84 (m, 1 H), 3.70 (m, 1

H), 3.33 (m, 1 H, J 8.0 Hz), 2.16, 2.15, 2.14, 2.09, 2.03, 2.02, 2.01, 1.99 (s each, 3 H each), 1.09 (d, 3 H, J 6.4 Hz); ESIMS (m/z): 858 [M + 1 + Na⁺], 853 [M⁺ + 1 + H₂O]. Anal. Calcd for C₃₆H₅₀O₂₂: C, 51.78; H, 6.00. Found: C, 51.54; H 6.20.

2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl- $(1 \rightarrow 2)$ - $[(2,3,4-tri - O - acetyl - \beta - D - xylopyran$ osvl)- $(1 \rightarrow 3)l$ -4-O-acetvl- α -D-fucopvranosvltrichloroacetimidate (2). To a mixture of 19 (200 mg, 0.24 mmol) in CH₃CN-H₂O (4:1, 15 mL), was added $C_6ClF_{12}I$ (135 mg, 0.29 mmol), followed by addition of a mixture of Na_2SO_4 (25 mg, 0.14 mmol) and $NaHCO_3$ (12 mg, 0.14 mmol). After stirring at rt for 1 h, the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na₂SO₄ and then concentrated to give a residue. To a solution of the above residue in dry EtOH (5 mL) was added Zn (40 mg, 0.6 mmol) and NH₄Cl (16 mg, 0.12 mmol). After refluxing for 10 min, the mixture was filtered. The filtrates were concentrated and then purified by silica gel column chromatography (1:1)petroleum ether-EtOAc) to give 20 (148 mg, 76%, a mixture of α , β anomers) as a white amorphous solid: ¹H NMR analysis confirmed the removal of allyl group. To a solution of 20 (100 mg, 0.12 mmol) and trichloroacetonitrile (0.12 mL, 1.2 mmol) in CH₂Cl₂ (1 mL) was added DBU (0.014 mL, 0.09 mmol) dropwise at 0 °C. The mixture was stirred for 30 min and then directly purified by silica gel column chromatography (2:1 petroleum ether-EtOAc) to afford 2 (95 mg, 81%) as a white foam: ¹H NMR (300 MHz, CDCl₃): δ 8.50 (s, 1 H), 6.40 (d, 1 H, J 3.5 Hz), 5.31 (d, 1 H, J 3.6 Hz), 5.08 (m, 3 H), 4.90 (m, 3 H), 4.60 (d, 1 H, J 6.4 Hz), 4.47 (d, 1 H, J 9.4 Hz), 4.15 (m, 6 H), 3.72 (m, 1 H), 3.42 (m, 1 H), 2.20–1.90 (m, 24 H), 1.10 (d, 3 H, J 6.3 Hz). Trichloroacetimidate 2 was not stable and was directly used in the next glycosylation reaction.

 $(25R) - 3\beta$ - tert - Butyldimethylsilyl - ruscogenin-1 β -yl 2,3,4-tri-O-acetyl- β -D-fucopyranoside (22).—A solution of 2 (38 mg, 0.070 mmol) in dry CH₂Cl₂ (3 mL) was stirred in the presence of 4 Å molecular sieves (5 mg) under argon at rt for 30 min. A solution of TMSOTf in CH_2Cl_2 (0.1 N, 1.4 µL) was then added dropwise, followed by the addition of trichloroacetimidate 21 (34 mg, 0.079 mmol). After stirring for 2 h, the mixture was treated with satd aq NaHCO₃ (4 mL) and then diluted with CH₂Cl₂ (20 mL). The organic layer was separated, dried over sodium sulfate, and then concentrated in vacuo. The residue was purified by silica gel column chromatography (2:1 petroleum ether-EtOAc) to give 22 (37 mg, 69%, based on 2) as a white solid: mp 75-76 °C; $[\alpha]_{D}^{20}$ - 26.6° (c 1.5, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 5.44 (brd, 1 H, J 5.5 Hz), 5.13 (m, 1 H), 5.02 (dd, 1 H, J 10.5, 7.4 Hz), 4.93 (m, 1 H), 4.35 (d, 1 H, J 7.4 Hz), 4.32 (m, 1 H), 3.66 (m, 1 H), 3.40-3.33 (m, 2 H), 3.29 (t, 1 H, J 10.8 Hz), 2.09, 1.97, 1.92 (s each, 3 H each), 1.11 (d, 3 H, J 6.3 Hz), 0.93 (s, 3 H), 0.88 (d, 3 H, J 6.9 Hz), 0.82 (s, 9 H), 0.74 (s, 3 H), 0.72 (d, 3 H, J 5.7 Hz); FABMS (m/z): 819 [M⁺ + 1], 818 [M⁺], 817 [M⁺ - 1]. (25R)-3-O- β -tert-Butyldimethylsilyl-rusco-2,3,4,6-tetra-O-acetyl-*β*-D-glugenin-1 β -vl $copyranosyl - (1 \rightarrow 2) - [(2,3,4-tri-O-acetyl-\beta-D-acetyl-\beta) - D-acetyl - \beta - D-acetyl - D-acetyl - \beta - D-acetyl - D-acetyl$ xylopyranosyl)- $(1 \rightarrow 3)$]-4-O-acetyl- β -D-fucopyranoside (23).—A solution of 2 (24 mg, 0.04 mmol) in dry CH_2Cl_2 (3 mL) was stirred in the presence of 4 Å molecular sieves (50 mg) under argon at rt for 30 min. Then a solution of TMSOTf in CH₂Cl₂ (0.1 N, 8 µL) was added dropwise. After stirring for 20 min, trichloroacetimidate 3 (100 mg, 0.11 mmol) was added. The mixture was stirred for another 2 h and then treated with satd aq NaHCO₃ (4 mL) and diluted with CH_2Cl_2 (20 mL). The organic layer was separated, dried over sodium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography (1:1)petroleum ether-EtOAc) to give 23 (16 mg, 46%) and its α anomer (3 mg, 10%) as white amorphous solids. 23: $[\alpha]_{D}^{20} - 49.2^{\circ}$ (c 0.09 in CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ 5.55 (brd, 1 H, J 5.7 Hz), 5.18 (t, 1 H, J 9.3 Hz), 5.16 (m, 1 H), 5.12 (m, 1 H, J 9.7 Hz), 5.07 (m, 1 H, J 6.9 Hz), 4.91–4.86 (m, 2 H), 4.89 (d, 1 H, J 7.8 Hz), 4.85 (t, 1 H, J 9.1 Hz), 4.84 (d, 1 H, J 7.7 Hz), 4.39 (m, 1 H), 4.37 (m, 1 H, J 3.9 Hz), 4.31 (d, 1 H, J 7.3 Hz), 4.12 (dd, 1 H, J 12.4, 3.6 Hz), 4.09 (dd, 1 H, J 12.1, 4.0 Hz), 3.81 (dd, 1 H, J 9.7, 3.3 Hz), 3.75 (dd, 1 H, J 9.7,

7.3 Hz), 3.68 (m, 1 H), 3.57 (m, 1 H), 3.47– 3.41 (m, 3 H), 3.37 (t, 1 H, *J* 10.5 Hz), 3.33 (dd, 1 H, *J* 12.1, 4.4 Hz); FABMS (m/z): 1321 [M⁺ + 1], 1320 [M⁺], 1265 [M⁺ + 1-OAc]. HREIMS: Calcd for C₆₆ H₁₀₀O₂₅Si: 1321.6350. Found: 1321.6401.

(25R)-Ruscogenin-1 β -yl β -D-glucopyran $osyl-(1 \rightarrow 2)$ - $[\beta$ -D- $xylopyranosyl-(1 \rightarrow 3)]-\beta$ -Dfucopyranoside (1).—Compound 23 (5 mg, 0.0038 mmol) was treated with TMSOTf (0.0095 mmol) in dry CH₂Cl₂ (3 mL) under argon for 10 min, followed by addition of neutral Al_2O_3 (3 mg), and then filtration. The filtrates were concentrated and dissolved in MeOH (2 mL) containing a catalytic amount of NaOMe. The mixture was stirred for 2 h and then concentrated to give a residue, which was purified by silica gel column chromatography (2:1 CH₂Cl₂–MeOH) to afford saponin 1 (2.8 mg, 85%) as a white amorphous solid: $[\alpha]_{\rm D}^{20} = -87.3^{\circ}$ (c 0.11, pyridine, lit. -90.3° , c 0.63 [1]); ¹H NMR (pyridine- d_5): δ 5.85 (d, 1) H, J 7.0 Hz), 5.78 (brd, 1 H, J 5.9 Hz), 5.47 (d, 1 H, J 7.8 Hz), 5.20 (d, 1 H, J 6.9 Hz), 4.93 (dd, 1 H, J 10.5 Hz), 4.86 (dd, 1 H, J 3.0 Hz), 4.65–4.62 (m, 3 H), 4.58 (dd, 1 H), 4.54 (dd, 1 H, J 11.2, 5.3 Hz), 4.40–4.37 (m, 2 H), 4.31– 4.27 (m, 4 H), 4.17 (t, 1 H, J 8.6 Hz), 4.15 (m, 1 H), 4.06 (dd, 1 H, J 11.8, 4.1 Hz), 3.90 (dd, 1 H, J 10.9 Hz), 3.88 (m, 1 H), 3.71 (m, 1 H), 3.65 (t, 1 H, J 10.6 Hz), 1.64 (d, 3 H, J 6.5 Hz), 1.47 (s, 3 H), 1.25 (d, 3 H, J 6.5 Hz), 1.12 (s, 3 H), 0.85 (d, 1 H, J 5.8 Hz); FABMS (m/z): 909 [M + K⁺], 893 [M + Na⁺], 871 $[M^+ + 1]$, 869 $[M^+ - 1]$. HREIMS (m/z): Calcd for C_{44} $H_{70}O_{17}$: 871.4676. Found: 871.4691.

Acknowledgements

This work was supported by the Ministry of Science and Technology of China and Hong Kong Industry Department. B.Yu thanks a grant from NSFC (29925203).

References

[1] G.-J. Xu, L.-S. Xu (Eds.), Species Systemization and Quality Evaluation of Commonly Used Traditional Chinese Herbs (Chin.), Fujian Science Press, Vol. 1, 1995, pp 56–113.

- [2] B.-Y. Yu, Y. Hirai, J. Shoji, G.-J. Xu, Chem. Pharm. Bull., 38 (1990) 1931–1935.
- [3] Q. Xu, R. Wang, B. Yu, J. Chin. Pharm. Univ., 24 (1993) 98-101; Chem. Abstr., 119 (1993) 40500.
- [4] M. Liu, B. Yu, Y. Hui, *Tetrahedron Lett.*, 39 (1998) 415–418.
- [5] (a) R.R. Schmidt, W. Kinzy, Adv. Carbohydr. Chem. Biochem., 50 (1994) 21–124. (b) R.R. Schmidt, Angew. Chem., Int. Ed. Engl., 25 (1986) 212–235.
- [6] (a) K. Gamoh, M. Hirayama, N. Ikekawa, J. Chem. Soc., Perkin Trans. 1, (1984) 449–454. (b) A. Von Furst, L. Labler, W. Meier, Helv. Chim. Acta, 64 (1981) 1870– 1892.
- [7] D. Freeman, A. Acher, Y. Mazur, *Tetrahedron Lett.*, (1975) 261–264.
- [8] (a) O. Mitsunobu, Synthesis, (1981) 1–28. (b) V.H. Loibner, E. Zbiral, Helv. Chim. Acta, 60 (1977) 417–425.
- [9] M. Noam, I. Tamir, E. Breuer, R. Mechoulam, *Tetrahedron*, 37 (1981) 597–604.
- [10] (a) L.M. Lerner, Carbohydr. Res., 19 (1971) 255–258. (b)
 X.-B. Han, R.R. Schmidt, Justus Liebigs Ann. Chem., (1992) 817–823.

- [11] (a) T. Ogawa, *Chem. Soc. Rev.*, (1994) 397–407. (b) R.
 Windmuller, R.R. Schmidt, *Tetrahedron Lett.*, 35 (1994) 7927–7930. (c) S. Deng, B. Yu, Y. Lou, Y. Hui, *J. Org. Chem.*, 64 (1999) 202–208.
- [12] (a) J.F. King, A.D. Allbutt, Can. J. Chem., 48 (1970) 1754–1769. (b) W. Zhou, H.J. Jennings, J. Carbohydr. Chem., 15 (1996) 279–295.
- [13] H.B. Mereyala, S. Guntha, *Tetrahedron Lett.*, 34 (1993) 6929–6930.
- [14] (a) J. Lüning, U. Möller, N. Debski, P. Welzel, *Tetrahedron Lett.*, 34 (1993) 5871–5874. (b) D. Mostowicz, M. Chmielewski, *Pol. J. Chem.*, 67 (1993) 1235–1241.
- [15] (a) B. Yu, J. Zhang, S. Lu, Y. Hui, *Synlett*, (1998) 29–30.
 (b) B. Yu, B. Li, J. Zhang, Y. Hui, *Tetrahedron Lett.*, 39 (1998) 4871–4874.
- [16] S.-F. Lu, Q.-Q. O'yang, Z.-W. Guo, B. Yu, Y. Hui, J. Org. Chem., 62 (1997) 8400–8405.
- [17] R.R. Schmidt, A. Toepfer, *Tetrahedron Lett.*, 32 (1991) 3353–3356.
- [18] T.D. Nelson, R.D. Crouch, Synthesis, (1996) 1031-1069.
- [19] C. Li, B. Yu, M. Liu, Y. Hui, Carbohydr. Res., 306 (1998) 189–195.